Your browser doesn't support javascript.
loading
CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma.
Walton, Josephine; Blagih, Julianna; Ennis, Darren; Leung, Elaine; Dowson, Suzanne; Farquharson, Malcolm; Tookman, Laura A; Orange, Clare; Athineos, Dimitris; Mason, Susan; Stevenson, David; Blyth, Karen; Strathdee, Douglas; Balkwill, Frances R; Vousden, Karen; Lockley, Michelle; McNeish, Iain A.
Affiliation
  • Walton J; Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom. Centre for Cancer and Inflammation, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
  • Blagih J; Cancer Research UK Beatson Institute, Glasgow, United Kingdom.
  • Ennis D; Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.
  • Leung E; Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.
  • Dowson S; Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.
  • Farquharson M; Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.
  • Tookman LA; Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
  • Orange C; Department of Pathology, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.
  • Athineos D; Cancer Research UK Beatson Institute, Glasgow, United Kingdom.
  • Mason S; Cancer Research UK Beatson Institute, Glasgow, United Kingdom.
  • Stevenson D; Cancer Research UK Beatson Institute, Glasgow, United Kingdom.
  • Blyth K; Cancer Research UK Beatson Institute, Glasgow, United Kingdom.
  • Strathdee D; Cancer Research UK Beatson Institute, Glasgow, United Kingdom.
  • Balkwill FR; Centre for Cancer and Inflammation, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
  • Vousden K; Cancer Research UK Beatson Institute, Glasgow, United Kingdom.
  • Lockley M; Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
  • McNeish IA; Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom. Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom. iain.mcneish@glasgow.ac.uk.
Cancer Res ; 76(20): 6118-6129, 2016 10 15.
Article in En | MEDLINE | ID: mdl-27530326
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Tumor Suppressor Protein p53 / Cystadenocarcinoma, Serous / BRCA2 Protein / Disease Models, Animal / CRISPR-Cas Systems Type of study: Prognostic_studies Limits: Animals Language: En Journal: Cancer Res Year: 2016 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Tumor Suppressor Protein p53 / Cystadenocarcinoma, Serous / BRCA2 Protein / Disease Models, Animal / CRISPR-Cas Systems Type of study: Prognostic_studies Limits: Animals Language: En Journal: Cancer Res Year: 2016 Document type: Article Affiliation country: Country of publication: